紫杉醇联合铂类疗效与Stathmin基因表达在卵巢癌中的相关性

Correlation between Efficacy of Paclitaxel Plus Platinum Platinum and Stathmin Gene Expression in Ovarian Cancer

目的探讨紫杉醇联合铂类在卵巢癌患者中的临床疗效及其与stathmin基因表达相关性。方法选取120例卵巢癌患者资料进行分析,将患者根据随机数字方法分为2组,每组60例。对照组采用伊立替康联合顺铂方案治疗,研究组采用紫杉醇联合铂类方案治疗,患者治疗前后利用免疫组化和逆转录聚合酶链反应(RT-PCR)方法检测stathmin基因表达,分析2组患者临床疗效及stathmin基因表达情况。结果研究组治疗总有效率为68.3%,显著高于对照组的57.1%(P<0.05)。2组患者治疗前stathmin基因表达水平差异不具有统计学意义(P>0.05);研究组治疗后stathmin基因表达水平,显著低于对照组(P<0.05)。结论卵巢癌患者采用紫杉醇联合铂类方案治疗效果理想,且stathmin基因表达越低,治疗预后越好,不良反应发生率低,值得推广应用。

Objective To investigate the clinical efficacy of paclitaxel plus platinum in patients with ovarian cancer and its correlation with stathmin gene expression .Methods 120 patients with ovarian cancer were randomly divided into 2 groups ,60 cases in each group .The control group received irinotecan plus cisplatin regimen ,and the experimental group received paclitaxel plus platinum regimens , stathmin gene expression were detected by immunohistochemistry and reverse transcription polymerase chain reaction（RT-PCR） before and after treatment,clinical efficacy and stathmin gene expression of the 2 groups were analyzed. Results The total effective rate of the experimental group was 68.3%,which was significantly higher than the control group , 57.1%（P〈0.05）;stathmin gene expression of the 2 groups of patients before treatment had no statistically significant difference （P〉0.05）;stathmin gene expression level of the experimental group after treatment was significantly lower than the control group （P〈0.05）.Conclusion Paclitaxel plus platinum for ovarian cancer is effective ,and the lower the stathmin gene expression,the better the prognosis ,it has low incidence of adverse reactions ,and should be widely applied .